Vatinee Y. Bunya

Vatinee Y. Bunya

Auto-generated profile, based on publicly available information

Vatinee Y. Bunya

Perelman School of Medicine, 3400 Civic Center Blvd, Philadelphia, PA 19104, USA; Scheie Eye Institute, 51 N 39th St, Philadelphia, PA 19104, USA

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 September 2020 in The Journal of Rheumatology
Verified
Journal Article
Open access
PDF file
SMSara S. McCoy
Sara S. McCoy
CBChristie M. Bartels
Christie M. Bartels
ISIan J. Saldanha
Ian J. Saldanha
VBVatinee Y. Bunya
Vatinee Y. Bunya
EAEsen K. Akpek
Esen K. Akpek
ABAlan N. Baer
Alan N. Baer
Objective.: To define the association between oral and systemic manifestations of Sjögren syndrome (SS) and quality of life (QOL).Methods.: We analyzed a cross-sectional survey conducted by the Sjögren’s Foundation in 2016, with 2961 eligible responses. We defined oral symptom and sign exposures as parotid gland swelling, dry mouth, mouth ulcers/sores, oral candidiasis, trouble speaking, choking or dysphagia, sialolithiasis or gland infection, and dental caries. Systemic exposures included interstitial lung disease, purpura/petechiae/cryoglobulinemia, vasculitis, neuropathy, leukopenia, interstitial nephritis, renal tubular acidosis, autoimmune hepatitis, primary biliary cholangitis, or lymphoma. Outcomes included SS-specific QOL questions generated by SS experts and patients.Results.: Using multivariable regression models adjusted for age, sex, race, and employment, we observed that mouth ulcers or sores, trouble speaking, and dysphagia were associated with poor quality of life. The following oral aspects had the greatest effect on the following QOL areas: (1) mouth ulcers/sores on the challenge and burden of living with SS (OR 4.26, 95% CI 2.89–6.28); (2) trouble speaking on memory and concentration (OR 4.24, 95% CI 3.28–5.48); and (3) dysphagia on functional interference (OR 4.25, 95% CI 3.13–5.79). In contrast, systemic manifestations were associated with QOL to a lesser extent or not at all.Conclusion.: Oral manifestations of SS, particularly mouth ulcers or sores, trouble speaking, and dysphagia, were strongly associated with worse QOL. Further study and targeted treatment of these oral manifestations provides the opportunity to improve quality of life in patients with SS.

5 April 2020 in Cornea
Verified
Journal Article
Open access
JGJohn A. Gonzales
John A. Gonzales
SSStephen C. Shiboski
Stephen C. Shiboski
VBVatinee Y. Bunya
Vatinee Y. Bunya
EAEsen K. Akpek
Esen K. Akpek
JRJennifer R. Rose-Nussbaumer
Jennifer R. Rose-Nussbaumer
TLTom Lietman
Tom Lietman
Purpose: To evaluate the ocular signs and tests for keratoconjunctivitis sicca (KCS) in the absence of a gold standard.Methods: Cross-sectional study of participants from the Sjögren's International Collaborative Clinical Alliance (SICCA) registry. Participants had oral/ocular/rheumatologic examinations, blood/saliva samples collected, and salivary gland biopsy. Latent class analysis (LCA) identified clusters of patients based on 3 to 4 predictor variables relating to signs or tests of KCS. The resulting model-based “gold standard” classification formed the basis for estimated sensitivity and specificity associated with these predictors.Results: A total of 3514 participants were enrolled into SICCA, with 52.9% classified as SS. LCA revealed a best-fit model with 2 groups. For the gold standard–positive group, an abnormal tear breakup time, ocular staining score (OSS), and Schirmer I had a sensitivity of 99.5%, 91.0%, and 47.4%, respectively. For the gold standard–negative group, an abnormal tear breakup time, OSS, and Schirmer I had a specificity of 32.0%, 84.0%, and 88.5%, respectively. OSS components (fluorescein and lissamine staining), exhibited a sensitivity of 82.6% and 90.5%, respectively, in the gold standard–positive group, whereas these signs in the gold standard–negative group had a specificity of 88.8% and 73.0%, respectively.Conclusions: OSS and its components (fluorescein and lissamine staining) differentiated 2 groups from each other better than other KCS parameters and had relatively high sensitivity and specificity.

20 May 2019 in Journal of Immunology Research
Verified
Journal Article
Open access
PDF file
LSLong Shen
Long Shen
JHJing He
Jing He
JKJill Kramer
Jill Kramer
VBVatinee Y. Bunya
Vatinee Y. Bunya

11 January 2023 in Ophthalmology Science
Verified
Journal Article
Open access
MZMegan Zhao
Megan Zhao
YYYinxi Yu
Yinxi Yu
GYGuishuang Ying
Guishuang Ying
PAPenny A. Asbell
Penny A. Asbell
VBVatinee Y. Bunya
Vatinee Y. Bunya
To evaluate how increasing age is associated with dry eye disease (DED) signs and symptoms in the Dry Eye Assessment and Management (DREAM) study. This study was undertaken to better understand how DED signs and symptoms differ across decades of life with goals to help assess detection and treatment of DED. Secondary analysis of the DREAM study. One hundred twenty, 140, 185, and 90 participants aged < 50, 50 to 59, 60 to 69, and ≥ 70 years, respectively. We performed a secondary analysis of data from the DREAM study, a multicenter randomized clinical trial, to evaluate the effect of omega-3 fatty acid supplementation for the treatment of DED. At baseline, 6 months, and 12 months follow-up, participants underwent an assessment of DED symptoms and signs using Ocular Surface Disease Index, Brief Pain Inventory, tear break-up time (TBUT) (in seconds), Schirmer test with anesthesia (mm/5 minutes), conjunctival staining, corneal staining, meibomian gland dysfunction evaluation, and tear osmolarity (mOsm/l). Multivariable generalized linear regression models were used to compare DED symptoms and signs across the 4 age groups among all participants and by sex. Scores of DED symptoms, individual signs, and composite scores of DED signs. Among 535 patients with DED, increasing age was significantly associated with worse TBUT (P = 0.01), corneal staining (P < 0.001), a composite severity score of DED signs (P = 0.007), and tear osmolarity (P = 0.001). Similar significant differences were found across 4 age groups of 334 women in TBUT, corneal staining score, composite severity score of DED signs, and tear osmolarity (all P < 0.05) but not in men. We found that corneal staining, TBUT, tear osmolarity, and a composite severity score of DED signs were significantly more severe with increasing age in women but not in men; worsening symptoms did not increase with increasing age. The author(s) have no proprietary or commercial interest in any materials discussed in this article.

1 March 2022 in Clinical Ophthalmology
Verified
Journal Article
Open access
PDF file
ZTZujaja Tauqeer
Zujaja Tauqeer
SJStephanie E Jinno
Stephanie E Jinno
CCCaroline W Chung
Caroline W Chung
MMMina Massaro-Giordano
Mina Massaro-Giordano
VBVatinee Y Bunya
Vatinee Y Bunya
Purpose: Ocular adverse events have been reported in association with dupilumab, a monoclonal antibody to treat allergic diseases including atopic dermatitis (AD). We describe clinical findings and treatment of dupilumab-related ocular complications. Patients and Methods: Retrospective study of 19 dupilumab-treated AD patients seen for a new ocular complaint. Primary outcomes were specific ocular exam findings (conjunctival injection, corneal fluorescein staining, blepharitis, meibomian gland dysfunction (MGD)), treatments, and follow-up. Results: Nineteen dupilumab-treated AD patients were included. Median age was 47 years (range 18– 73). Over half were women (11/19) and majority were Caucasian (13/19). Symptom onset occurred at a mean of 99 days (range 23– 520 days) from first dupilumab dose. The most common symptoms were redness (63%), tearing (47%), and pruritus (37%). Most common ocular findings were conjunctival injection (75%) and corneal staining (60%). Blepharitis was seen in about a third (30%), and 25% had MGD. Initially, 10% were observed without treatment, while 15% were treated with artificial tears alone. Other treatments included antihistamine drops (20%) and steroid drops alone (15%). In 40% of patients, a combination of steroids and various other topical eye drops were prescribed. Eighty-four percent (16/19) of patients were seen for follow-up. Steroid drops were required at follow-up in 3 out of 4 patients initially treated with antihistamines alone and in two-thirds of patients initially treated with artificial tears only. Mean follow-up period was 88 days (range 5– 369). Dupilumab was discontinued in 31.5% (6/19) of patients; of those who discontinued, 3 restarted it later. Conclusion: Conjunctival injection was the most frequent dupilumab-related ocular symptom and most common exam finding followed by corneal staining. Most patients initially treated with antihistamine drops or artificial tears alone subsequently required steroid drops to control symptoms. Some patients who discontinued dupilumab restarted the medication after achieving adequate control of ocular symptoms.

1 April 2010 in Cornea
Verified
Journal Article
Closed access
AOAnton Orlin
Anton Orlin
SOStephen E Orlin
Stephen E Orlin
GMGeorge A Makar
George A Makar
VBVatinee Y Bunya
Vatinee Y Bunya
To report a case of presumed bilateral corneal copper deposition secondary to oral contraceptive use. A 23-year-old woman was referred for evaluation of bilateral corneal opacities. The location of the deposits deep in Descemet's membrane and appearance made copper deposition a likely consideration. Subsequent laboratory results revealed an elevated serum copper level (189 μg/dL). Other causes of cupremia were subsequently ruled out, and the patient's corneal copper deposition was attributed to her oral contraceptive use. With cessation of the oral contraceptive, her serum copper levels normalized, but the corneal deposits remained after 5 months of follow up. To our knowledge, we report the first case in the ophthalmic literature of presumed corneal copper deposition in the setting of oral contraceptive use. It is important to recognize the corneal findings associated with copper deposition, because it may lead to the diagnosis and treatment of other serious systemic conditions causing elevated serum copper levels.